Evidence map›Paper›PMID 39900438›Full record

ArticleLife science alliance2025

Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.

Anton Petcherski, Brett M Tingley, Andrew Martin, Sarah Adams, Alexandra J Brownstein, Ross A Steinberg, Byourak Shabane, Jennifer Ngo, Corey Osto, Gustavo Garcia and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anton PetcherskiDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-3143-3867
Brett M TingleyDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0001-8980-8679
Andrew MartinDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0002-7512-5049
Sarah AdamsDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0002-9527-8157
Alexandra J BrownsteinDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-0920-722X
Ross A SteinbergDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-3530-2557
Byourak ShabaneDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-9249-5917
Jennifer NgoDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-5829-6866
Corey OstoDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0009-0007-5622-7393
Gustavo GarciaDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-1649-9251
Michaela VeliovaDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-1117-691X
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-6872-5118
Aaron H ColbyDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0001-7161-821X
Orian S ShirihaiDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA oshirihai@mednet.ucla.edu.ORCID 0000-0001-8466-3431
Mark W GrinstaffDepartment of Biomedical Engineering, Boston University, Boston, MA, USA mgrin@bu.edu.ORCID 0000-0002-5453-3668

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 can infect cells through endocytic uptake, a process that is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here, we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, are 100-150 nm in diameter, and possess a negative surface charge, which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2 WA1 and its Omicron variant in a human lung epithelium model. Organelle-targeted delivery is an effective means to inhibit viral infection.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentLysosomesNanoparticle Drug Delivery SystemNanoparticlesSARS-CoV-2AnimalsCOVID-19Drug Delivery SystemsEndocytosisEndosomesHumansHydroxychloroquineLungMiceAntiviral AgentsHydroxychloroquineNanoparticle Drug Delivery System

Identifiers

PMID39900438
PMCPMC11790838

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.